Search Results 381-390 of 18368 for alopecia

1. Testing Olaparib and Temozolomide Versus the Usual Treatment for Uterine Leiomyosarcoma After Chemotherapy Has Stopped Working - Mayo Clinic

   (which must be ≤ grade 2), alopecia and/or endocrinopathies related to prior immunotherapy which are controlled with hormone replacement. - Patients must ...

2. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   - Patients who have recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia.

3. A Study of ONO-7475 in Patients With Acute Leukemias - Mayo Clinic

   Patients not recovered to Grade 1 or stabilized from the effects (excluding alopecia) of any prior therapy for their malignancies. Concurrent treatment with ...

4. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Seborrheic dermatitis, Melasma, Vitiligo. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann ...

5. Head and neck cancers - Doctors and departments - Mayo Clinic

   ... Alopecia areata, Melasma. Show more areas of focus for Ashley B. Wentworth, M.D.. Josh P. Wiedermann, M.D.. Otolaryngologist. Rochester ...

6. Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer - Mayo Clinic

   Experienced resolution of toxic effect(s) of the most recent prior chemotherapy to Grade 1 or less (except alopecia). If patient underwent major surgery or ...

7. Glembatumumab Vedotin in Treating Patients With Metastatic or Locally Recurrent Uveal Melanoma - Mayo Clinic

   All prior treatment-related toxicities must be Common Terminology Criteria for Adverse Events (CTCAE) version (v) 4 grade =< 1 (except alopecia); certain ...

8. A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer - Mayo Clinic

   ... alopecia or peripheral neuropathy. Have discontinued all previous therapies for cancer (including chemotherapy, radiotherapy, immunotherapy, and endocrine ...

9. Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer - Mayo Clinic

   ... alopecia and other non-clinically significant adverse events (AEs); The subject has active brain metastases or epidural disease; subjects with brain ...

10. Study Of SIM0500 Alone In Participants With Relapsed Or Refractory Multiple Myeloma - Mayo Clinic

    Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy. 2 ...